Stay updated on Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.

Latest updates to the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2. No substantive study information appears to be affected.SummaryDifference0.1%

- Check20 days agoChange DetectedThe funding-status notice banner was removed from the page. It previously warned about potential delays and pointed to NIH and government updates for status information.SummaryDifference0.4%

- Check41 days agoChange DetectedNo significant additions or deletions were detected on the page; the study details and eligibility criteria appear unchanged.SummaryDifference0.4%

- Check63 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference3%

- Check70 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

- Check84 days agoChange DetectedPage version updated from v3.0.1 to v3.0.2 and the 'Back to Top' link was removed. No substantive content changes were detected.SummaryDifference0.2%

Stay in the know with updates to Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.